{"id":15044,"date":"2025-08-22T00:34:21","date_gmt":"2025-08-22T00:34:21","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/15044\/"},"modified":"2025-08-22T00:34:21","modified_gmt":"2025-08-22T00:34:21","slug":"ionis-gets-approval-for-preventing-attacks-in-rare-and-genetic-hae","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/15044\/","title":{"rendered":"Ionis gets approval for preventing attacks in rare and genetic HAE"},"content":{"rendered":"<p>In Ionis Pharmaceuticals Inc.\u2019s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and genetic disease hereditary angioedema (HAE). The approval came as scheduled as the NDA had a PDUFA date of Aug. 21. Dawnzera now joins a market with previously approved drugs for the rare, genetic, life-threatening condition, as well as other companies with HAE drugs in development.<\/p>\n<p><a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/84-bioworld\" rel=\"nofollow noopener\" target=\"_blank\">BioWorld<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/402-regulatory\" rel=\"nofollow noopener\" target=\"_blank\">Regulatory<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/242-dermatologic\" rel=\"nofollow noopener\" target=\"_blank\">Dermatologic<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/271-antisense\" rel=\"nofollow noopener\" target=\"_blank\">Antisense<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/433-fda\" rel=\"nofollow noopener\" target=\"_blank\">FDA<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"In Ionis Pharmaceuticals Inc.\u2019s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as&hellip;\n","protected":false},"author":2,"featured_media":15045,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[272],"tags":[13160,13694,13700,13702,13699,18,2898,13696,458,13697,19,13695,17,13698,2912,13701,133],"class_list":["post-15044","post","type-post","status-publish","format-standard","has-post-thumbnail","category-genetics","tag-antisense","tag-bioworld","tag-dawnzera","tag-dermatologic","tag-donidalorsen","tag-eire","tag-fda","tag-genetic-diseases","tag-genetics","tag-hereditary-angioedema","tag-ie","tag-ionis-pharmaceuticals-inc","tag-ireland","tag-prophylactic-therapies","tag-rare-disease","tag-regulatory","tag-science"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/15044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=15044"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/15044\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/15045"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=15044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=15044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=15044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}